 |
인쇄하기
취소
|
Boehringer’s SGLT-2 complex, Synjardy, is expected to be approved this month
The complex of the Boehringer Ingelheim’s SGLT-2-inhibitor antidiabetic agent, Jardiance(empagliflozin), and metformin will enter the domestic market this month at the fastest.
The product name of the complex will be ‘Synjardy’ and is expected to be approved on the 23rd.
Currently, the AstraZeneca’s ‘Xigduo(Forxiga + metformin)’ is the only complex of a domestically-approved SGLT-2 inhibitor ...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.